Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine
Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine
Engineering, and Medicine National Academies of Sciences, Institute of Medicine, Board on Health Care Services, Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies
Language: English | 2016 | ISBN: 0309381347 | 292 pages | PDF | 3,1 MB
Engineering, and Medicine National Academies of Sciences, Institute of Medicine, Board on Health Care Services, Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies
Language: English | 2016 | ISBN: 0309381347 | 292 pages | PDF | 3,1 MB
Every patient is unique, and the evolving field of precision medicine aims to ensure the delivery of the right treatment to the right patient at the right time. In an era of rapid advances in biomedicine and enhanced understanding of the genetic basis of disease, health care providers increasingly have access to advanced technologies that may identify molecular variations specific to an individual patient, which subsequently can be targeted for treatment. Known as biomarker tests for molecularly targeted therapies, these complex tests have the potential to enable the selection of the most beneficial treatment (and also to identify treatments that may be harmful or ineffective) for the molecular underpinnings of an individual patient’s disease. Such tests are key to unlocking the promise of precision medicine.